Celgene spondylitis drug misses main goal in late-stage study
July 9 (Reuters) - Celgene Corp said its experimental drug for the treatment of a type of arthritis that affects the spine failed to meet the main goal in a late-stage study, sending its shares down 3 percent premarket.
Patients suffering from ankylosing spondylitis who were treated with the drug, Otezla, failed to show statistically significant response compared to those on a placebo, the company said.
However, an independent data monitoring committee recommended that the study should continue unchanged. (Reporting By Penumudi Amrutha; Editing by Sriraj Kalluvila)
- U.S., Arab partners launch first strikes on IS in Syria |
- Qatar adamant it will host 2022 World Cup despite doubts
- Argentina's Fernandez to meet billionaire investor Soros in New York
- Ebola could strike 20,000 in six weeks, 'rumble on for years': study
- More Americans than ever have never married: survey